Hypoglycemia in cystic fibrosis during an extended oral glucose tolerance test.
abnormal glucose metabolism
cystic fibrosis
hypoglycemia
oral glucose tolerance test
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
27
01
2020
revised:
01
09
2020
accepted:
02
09
2020
pubmed:
22
9
2020
medline:
6
3
2021
entrez:
21
9
2020
Statut:
ppublish
Résumé
Hypoglycemia in cystic fibrosis (CF), in the absence of glucose-lowering therapies, has long been identified as an important issue in the management of CF. There is currently still no unifying hypothesis for its etiology. The aims of this study were to perform a 3-h oral glucose tolerance test (OGTT) in participants with CF and (1) document glucose, insulin, glucagon, glucagon-like-peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP) release patterns within varying glucose tolerance groups during the OGTT; (2) determine the prevalence of hypoglycemic during the OGTT; and (3) define any association between hypoglycemia and patterns of insulin, glucagon, GLP-1, and GIP release. Eligible participants attending an adult CF clinic completed a 3-h OGTT. Hypoglycemia on OGTT was defined as mild (glucose 3.4-3.9 mmol/L), moderate (glucose 3.1-3.3 mmol/L), and severe (glucose ≤ 3 mmol/L). Hormones were measured at fasting, 30, 60, 120, and 180 min. Twenty-four participants completed the study, of which 7 had normal glucose tolerance, 12 had abnormal glucose tolerance, and 5 had cystic fibrosis related diabetes (CFRD). All participants had a delayed insulin response compared with normative data. All glucose tolerance groups showed appropriate and similar suppression of fasting glucagon. Four participants (17%) had mild hypoglycemic, three (13%) had moderate hypoglycemic, and eight (33%) had severe hypoglycemic. No participant with CFRD demonstrated hypoglycemic. Of the 19 participants without CFRD, 15 (79%) experienced hypoglycemic. Participants with hypoglycemic had greater peak glucose and insulin responses than those that did not have hypoglycemic, and this approached significance (p = .0625 for glucose and p = .0862 for insulin). No significant mean differences between GLP-1 and GIP release were found. There was no relationship between hypoglycemic and modulator therapy. Postprandial hypoglycemic was unmasked by the extension of an OGTT to 3 h. Delayed and abnormal insulin release, and ineffective counter-regulatory action of glucagon may have a role in its etiology.
Sections du résumé
BACKGROUND
Hypoglycemia in cystic fibrosis (CF), in the absence of glucose-lowering therapies, has long been identified as an important issue in the management of CF. There is currently still no unifying hypothesis for its etiology.
AIM
The aims of this study were to perform a 3-h oral glucose tolerance test (OGTT) in participants with CF and (1) document glucose, insulin, glucagon, glucagon-like-peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP) release patterns within varying glucose tolerance groups during the OGTT; (2) determine the prevalence of hypoglycemic during the OGTT; and (3) define any association between hypoglycemia and patterns of insulin, glucagon, GLP-1, and GIP release.
METHODS
Eligible participants attending an adult CF clinic completed a 3-h OGTT. Hypoglycemia on OGTT was defined as mild (glucose 3.4-3.9 mmol/L), moderate (glucose 3.1-3.3 mmol/L), and severe (glucose ≤ 3 mmol/L). Hormones were measured at fasting, 30, 60, 120, and 180 min.
RESULTS
Twenty-four participants completed the study, of which 7 had normal glucose tolerance, 12 had abnormal glucose tolerance, and 5 had cystic fibrosis related diabetes (CFRD). All participants had a delayed insulin response compared with normative data. All glucose tolerance groups showed appropriate and similar suppression of fasting glucagon. Four participants (17%) had mild hypoglycemic, three (13%) had moderate hypoglycemic, and eight (33%) had severe hypoglycemic. No participant with CFRD demonstrated hypoglycemic. Of the 19 participants without CFRD, 15 (79%) experienced hypoglycemic. Participants with hypoglycemic had greater peak glucose and insulin responses than those that did not have hypoglycemic, and this approached significance (p = .0625 for glucose and p = .0862 for insulin). No significant mean differences between GLP-1 and GIP release were found. There was no relationship between hypoglycemic and modulator therapy.
CONCLUSION
Postprandial hypoglycemic was unmasked by the extension of an OGTT to 3 h. Delayed and abnormal insulin release, and ineffective counter-regulatory action of glucagon may have a role in its etiology.
Substances chimiques
Blood Glucose
0
Insulin
0
Gastric Inhibitory Polypeptide
59392-49-3
Glucagon-Like Peptide 1
89750-14-1
Glucagon
9007-92-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3391-3399Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-1631.
Moranoran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care. 2010;33(12):2677-2683.
Moranoran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-2708.
Battezzatiattezzati A, Battezzati PM, Costantini D, et al. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur J Endocrinol. 2007;156(3):369-376.
Armaghanian N, Brand-Miller JC, Markovic TP, Steinbeck KS. Hypoglycaemia in cystic fibrosis in the absence of diabetes: a systematic review. J Cyst Fibros. 2016;15(3):274-284.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90.
Andrew U. Dumping syndrome: pathophysiology and treatment. Nutr Clin Pract. 2005;20(5):517-525.
Moran A, Pillay K, Becker DJ, Acerini CL. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2014;15(S20):65-76.
Brunzell C, Hardin DS, Moran A, Schindler T, Schissel K. Managing Cystic Fibrosis-Related Diabetes (CFRD): An Instruction Guide for Patients and Families. 4th ed. Maryland, USA: Cystic Fibrosis Foundation; 2008.
Cystic Fibrosis Trust, UK, Cystic fibrosis-related diabetes, [Internet, last updated 2012]. https://www.cysticfibrosis.org.uk/media/127524/FS_Related_Diabetes_Mar_13.pdf. Accessed October 8, 2015.
Lanng S, Thorsteinsson B, Røder ME, et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol. 1993;128(3):207-214.
Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr. 1991;118(5):715-723.
McCrimmon R. The mechanisms that underlie glucose sensing during hypoglycaemia in diabetes. Diabetic Med. 2008;25(5):513-522.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36(5):1396-405.
Ross SA, Morrison D, McArthur RC. Hypersecretion of gastric inhibitory polypeptide in nondiabetic children with cystic fibrosis. Pediatrics. 1981;67(2):252-254.
Kuo P, Stevens JE, Russo A, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis: effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab. 2011;96(5):E851-E855.
Wang X, Zhao X, Zhou R, et al. Delay in glucose peak time during the oral glucose tolerance test as an indicator of insulin resistance and insulin secretion in type 2 diabetes patients. J Diabetes Investig. 2018;9:1288-1295.
Hameed S, Morton JR, Jaffe A, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care. 2010;33(2):221-226.
Lippe BM, Sperling MA, Dooley RR. Pancreatic alpha and beta cell functions in cystic fibrosis. J Pediatr. 1977;90(5):751-755.
Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109-115.
Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros. 2012;11(2):144-149.
Adrian TE, McKiernan J, Johnstone DI, et al. Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology. 1980;79(3):460-465.
Allen JM, Penketh ARL, Adrian TE, et al. Adult cystic stic fibrosis: postprandial response of gut regulatory peptides. Gastroenterology. 1983;85(6):1379-1383.
Matsuo T, Kusunoki Y, Katsuno T, et al. Response of incretins (GIP and GLP-1) to an oral glucose load in female and male subjects with normal glucose tolerance. Diabetes Res Clin Pract. 2014;106(2):e25-e29.
Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
Armaghanian N, Markovic TP, Brand-Miller JC, Bye PTP, Moriarty CP, Steinbeck KS. Hypoglycaemia in cystic fibrosis: an analysis of a single centre adult cystic fibrosis clinic. J Cyst Fibros. 2018;17(4):542-547.
Moheet A, Ode KL. Hypoglycaemia in patients with cystic fibrosis-harbinger of poor outcomes or innocent bystander? J Cyst Fibros. 2018;17(4):428-429.
Lev-Ran A. Nadirs of oral glucose tolerance tests are independent of age and sex. Diabetes Care. 1983;6(4):405-408.
Hirsch IB, Janci MM, Goss CH, Aitken ML. Hypoglycemia in adults with cystic fibrosis during oral glucose tolerance testing. Diabetes Care. 2013;36(8):e121-e122.
Adler A, Gunn E, Haworth C, Bilton D. Biochemical hypoglycemia during oral glucose tolerance testing - Not more common in adults with cystic fibrosis. Pediatr Pulmonol. 2007:394.
Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M. Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis-related diabetes. Diabetes Care. 2011;34(4):e43.
Seltzer HS, Fajans SS, Conn JW. Spontaneous hypoglycemia as an early manifestation of diabetes mellitus. Diabetes. 1956;5(6):437-442.
Mannik LA, Chang KA, Annoh PQK, et al. Prevalence of hypoglycemia during oral glucose tolerance testing in adults with cystic fibrosis and risk of developing cystic fibrosis-related diabetes. J Cyst Fibros. 2018;17:536-541.